STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5818-5828

  Wang, Ling ^a   Jin, Yang ^a   Arnoldussen, Yke Jildouw ^a   Jonson, Ida ^a   Qu, Su ^a   Mælandsmo, Gunhild M ^a,b   Kristian, Alexandr ^a,b   Risberg, Bjørn ^a,b   Wæhre, Håkon ^a,b   Danielsen, Håvard E ^a,b   Saatcioglu, Fahri ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN STAMP1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHROMONES; COS CELLS; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MORPHOLINES; NEOPLASM PROTEINS; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77955048177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4697     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
3. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93: 1687-97.
4. Herness EA, Naz RK. A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis. Cancer Res 2003;63:329-36.
5. Korkmaz CG, Korkmaz KS, Kurys P, et al. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005;24:4934-45.
6. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 2002;277:36689-96.
7. Naz RK, Herness EA. Prostate-specific genes: present status and future direction. Front Biosci 2001;6:D1083-8.
8. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43.
9. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001; 61:3760-9.
10. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM. Molecular markers of prostate cancer. Urol Oncol 2006;24:538-51.
11. Porkka KP, Helenius MA, Visakorpi T. Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate. Lab Invest 2002;82:1573-82.
12. Wellen KE, Fucho R, Gregor MF, et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007;129:537-48.
13. Steiner MS, Zhang X, Wang Y, Lu Y. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. Cancer Res 2000;60:4419-25.
14. Passer BJ, Nancy-Portebois V, Amzallag N, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc Natl Acad Sci U S A 2003; 100:2284-9.
15. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006;108:1388-94.
16. Klokk TI, Kilander A, Xi Z, et al. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 2007;67:5221-30.
17. Lorenzo PI, Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 2008;10:418-28.
18. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365-70.
19. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
20. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
21. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
22. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002;21:1017-27.
23. Arnoldussen YJ, Lorenzo PI, Pretorius ME, et al. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res 2008;68:9255-64.
24. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276: 10767-74.
25. Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007;29:1227-38.
26. Arnoldussen YJ, Saatcioglu F. Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol 2009;309:1-7.
27. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
28. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-6.
29. de Mattia F, Gubser C, van Dommelen MM, et al. Human Golgi antiapoptotic protein modulates intracellular calcium fluxes. Mol Biol Cell 2009;20:3638-45.
30. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66:7237-44.
31. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
32. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008;40:2707-19.
33. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 2002;33:299-306.
34. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
35. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003;55:128-39.
36. Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 2008;57: 259-65.
37. Pang X, Yi T, Yi Z, et al. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 2009;69: 518-25.
38. Carey AM, Pramanik R, Nicholson LJ, et al. Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 2007;121:520-7.
39. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162:1537-42.
40. Reddy GP, Barrack ER, Dou QP, et al. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 2006;98:1408-23.
41. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005;11:1704-12.